-
Otsuka Holdings Weighs Sale of Stake in Medical Device Maker MicroPort Scientific
•
Otsuka Holdings Co., a Japanese pharmaceutical and healthcare company, is reportedly considering the sale of its shares in Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853), according to a Bloomberg report. The company is said to be working with financial advisors to assess its minority stake in MicroPort after…
-
MicroPort CardioFlow’s Heart Valve Balloon Dilatation Catheter Alwide Plus Gains Mexican Approval
•
MicroPort Scientific Corp., a leading Chinese medical device company (HKG: 0853), through its spin-off MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), has announced that it has received market approval for its heart valve balloon dilatation catheter, Alwide Plus, from the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) in…
-
MicroPort Scientific’s Firesorb Bioabsorbable Stent Begins Clinical Use in China
•
MicroPort Scientific Corp., a leading medical device company based in Shanghai (HKG: 0853), has announced the initial clinical applications of its new-generation bioabsorbable stent, Firesorb, across seven clinical centers in five Chinese cities. The product received marketing approval in China in July this year. Firesorb is a bioabsorbable rapamycin targeted…
-
MicroPort Medical Reports 17% Revenue Growth in 2024H1, Driven by Subsidiaries’ Performance
•
HONG KONG—MicroPort Medical Science and Technology Co., Ltd (HKG: 0853), a leading medical device company, has released its financial report for the first half of 2024, showing a revenue increase of 17.0% year-on-year to $559 million, excluding the impact of currency exchange rates. The company’s loss for the period was…
-
MicroPort CardioFlow to Acquire RMB 380 Million Shanghai Assets for Global HQ Expansion
•
China-based MicroPort Scientific Corp. (HKG: 0853) has announced that its spin-off, MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), will acquire a 100% stake in Shanghai Heart Forever Medical Technology Co., Ltd. The acquisition, valued at up to RMB 380 million, will be executed through a transfer from its sister company,…
-
MicroPort Scientific’s Bioabsorbable Stent System Gains NMPA Nod for Ischemic Heart Disease Treatment
•
Shanghai-based medical device conglomerate MicroPort Scientific Corp. (HKG: 0853) has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its proprietary bioabsorbable rapamycin eluting coronary stent system. This innovative device is designed for the treatment of patients suffering from ischemic heart disease due to…
-
MicroPort Scientific’s Fully Biodegradable Cardiac Stent Earns NMPA Nod
•
Shanghai-based medical device titan MicroPort Scientific Corp. (HKG: 0853) has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its new generation fully biodegradable and absorbable cardiac stent. This innovation marks a significant advancement in the field of interventional cardiology. The stent is the…
-
MicroPort CardioFlow Secures Exclusive Distribution Rights for Evermend Occluders in China
•
MicroPort Scientific Corp (HKG: 0853), a leading medical device company based in China, has announced that its spin-off, MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), has entered into a distribution framework agreement with Dongguan Kewei Medical Instrument Co., Ltd. Kewei, which was acquired by MicroPort Scientific in 2012, has agreed…
-
MicroPort Scientific Corp’s Subsidiaries Forecast Significant H1 2024 Revenue Growth
•
MicroPort Scientific Corp (HKG: 0853), a leading medical device company, has seen its subsidiaries Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) and spin-off MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) unveil their financial forecasts for the first half of 2024, along with business updates. MedBot anticipates a significant year-on-year…
-
MicroPort CardioFlow Medtech’s AltaValve Receives FDA Breakthrough Designation for Mitral Regurgitation Treatment
•
MicroPort Scientific Corp (HKG: 0853), a leading medical device company based in China, has announced that its spin-off, MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), has received Breakthrough Devices status from the US Food and Drug Administration (FDA) for its AltaValve transcatheter mitral valve replacement device. This product, co-developed with…
-
MicroPort CardioFlow Medtech’s VitaFlow Liberty Receives CE Mark for European Expansion
•
China-based MicroPort Scientific Corp (HKG: 0853), a leading medical device company, announced that its spin-off, MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), has secured the CE mark for its VitaFlow Liberty transcatheter aortic valve and its recyclable delivery system. This regulatory approval paves the way for the product’s market entry…
-
MicroPort CardioFlow Medtech Reports 33.9% YOY Revenue Growth in 2023 Financials
•
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG: 0853), has announced its financial report for 2023. The company reported a 33.9% year-on-year (YOY) increase in revenue, reaching RMB 336 million (USD 46.5 million), with gross profits surging 41.8% to RMB 223 million (USD…
-
MicroPort CardioFlow Forecasts 31%-36% YOY Sales Growth for 2023 Driven by TAVI Product Expansion
•
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG: 0853), has announced a forecast for its 2023 financial performance along with key business updates. The company anticipates generating sales within the range of RMB 330 million to RMB 340 million for the year, reflecting…
-
MicroPort CRM Receives NMPA Approval for Next-Generation MRI-Safe Implantable Cardiac Pacing System
•
MicroPort Scientific Corp. (HKG: 0853), a leading Shanghai-based medical device company, has announced that its France-based subsidiary MicroPort Cardiac Rhythm Management Limited (MicroPort CRM) has received a market license from the National Medical Products Administration (NMPA) for its next-generation intravenous magnetic resonance conditionally safe implantable cardiac pacing system. The product…
-
MicroPort Scientific Corp. Forecasts 31%-34% Revenue Growth for Subsidiary MicroPort Endovascular in 2023
•
Shanghai-based medical device conglomerate MicroPort Scientific Corp., (HKG: 0853) has issued a revenue and growth forecast for its subsidiary Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), in which it holds a 40.32% stake. MicroPort Endovascular is anticipated to achieve revenues within the range of RMB 1.17-1.2 billion (USD 168-238…
-
MicroPort CardioFlow Medtech’s AnchorMan System Receives NMPA Approval as First Semi-Closed LAA Occluder in China
•
MicroPort Scientific Corp (HKG: 0853), a leading medical device company based in China, has announced that its spin-off, MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), has received marketing approval from the National Medical Products Administration (NMPA) for La Ronda’s AnchorMan left atrial appendage occluder system. This marks the first semi-closed…
-
MicroPort CardioFlow Medtech to Acquire Controlling Stake in La Ronda for USD 20 Million
•
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG: 0853), has announced that a conditional agreement has been reached to acquire a 51% stake in fellow Chinese firm La Ronda for a cash consideration of RMB 141 million (USD 20 million). La Ronda, based…
-
MicroPort CardioFlow Medtech Completes Clinical Implantations of Second-Generation TAVI Device
•
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG: 0853), has announced the successful completion of seven clinical implantations of its second-generation transcatheter aortic valve implantation (TAVI) product, VitaFlow Liberty. The surgeries were performed in Denmark and Ireland, with all patients recovering well post-operation.…
-
MicroPort CardioFlow Medtech’s Third-Generation TAVI Product Achieves Initial Clinical Success
•
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG: 0853), has announced the successful completion of the first two clinical applications of its third-generation transcatheter aortic valve implantation (TAVI) product. This advanced medical device features a recyclable and controllable bend delivery system, which was…
-
MicroPort Secures Market Approvals for ULYS ICDs and INVICTA Leads in Japan
•
Shanghai-based MicroPort Scientific Corp. (HKG: 0853) has announced that its France-based subsidiary, MicroPort Cardiac Rhythm Management Limited (MicroPort CRM), has received market approvals for its ULYS implantable cardioverter defibrillators (ICDs) and INVICTA defibrillation electrode leads in Japan. This milestone marks a significant expansion for MicroPort in the Japanese medical device…
-
MicroPort Scientific Reports 19% Revenue Growth in H1 2023, Driven by Diverse Interventions
•
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has released its financial report for the first half of 2023, showcasing impressive revenue growth of 19% year-on-year (YOY) to USD 493 million. The company also reported a 13% reduction in losses, totaling USD 220 million. This performance highlights the company’s…
